Latest Insider Transactions at Phreesia, Inc. (PHR)
This section provides a real-time view of insider transactions for Phreesia, Inc. (PHR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Phreesia, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Phreesia, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 28
2024
|
Yvonne Hui Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
740
+4.42%
|
$13,320
$18.02 P/Share
|
|
Jun 28
2024
|
Allison C Hoffman General Counsel & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
292
+0.21%
|
$5,256
$18.02 P/Share
|
|
Jun 26
2024
|
Michael Weintraub Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,490
+4.3%
|
-
|
|
Jun 26
2024
|
Edward L Cahill Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,490
+13.46%
|
-
|
|
Jun 26
2024
|
Lainie Goldstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,490
+17.45%
|
-
|
|
Jun 26
2024
|
Lisa Egbuonu Davis Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,490
+30.29%
|
-
|
|
Jun 26
2024
|
Mark Douglas Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,490
+21.69%
|
-
|
|
Jun 26
2024
|
Ramin Sayar Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,490
+24.1%
|
-
|
|
Jun 26
2024
|
Gillian Munson Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,490
+19.18%
|
-
|
|
Jun 21
2024
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Indirect |
27
-0.39%
|
$540
$20.24 P/Share
|
|
Jun 21
2024
|
Janet Gunzburg Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
114
-0.33%
|
$2,280
$20.24 P/Share
|
|
Jun 20
2024
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Indirect |
66
-0.94%
|
$1,254
$19.73 P/Share
|
|
Jun 18
2024
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Indirect |
41
-0.58%
|
$779
$19.2 P/Share
|
|
May 01
2024
|
Janet Gunzburg Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
286
-0.81%
|
$6,006
$21.0 P/Share
|
|
Apr 30
2024
|
Edward L Cahill Director |
BUY
Grant, award, or other acquisition
|
Direct |
482
+1.04%
|
$9,640
$20.74 P/Share
|
|
Apr 30
2024
|
Gillian Munson Director |
BUY
Grant, award, or other acquisition
|
Direct |
482
+1.74%
|
$9,640
$20.74 P/Share
|
|
Apr 30
2024
|
Lainie Goldstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
482
+1.5%
|
$9,640
$20.74 P/Share
|
|
Apr 18
2024
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Indirect |
269
-3.66%
|
$5,918
$22.85 P/Share
|
|
Apr 18
2024
|
Janet Gunzburg Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
912
-2.52%
|
$20,064
$22.85 P/Share
|
|
Apr 15
2024
|
Allison C Hoffman General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
1,238
-0.9%
|
$27,236
$22.86 P/Share
|
|
Apr 15
2024
|
Evan Roberts Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,029
-0.27%
|
$44,638
$22.86 P/Share
|
|
Apr 15
2024
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
2,212
-1.07%
|
$48,664
$22.86 P/Share
|
|
Apr 15
2024
|
Amy Beth Van Duyn SVP, Human Resources |
SELL
Open market or private sale
|
Direct |
685
-0.57%
|
$15,070
$22.86 P/Share
|
|
Apr 15
2024
|
Chaim Indig Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,392
-0.28%
|
$74,624
$22.86 P/Share
|
|
Apr 15
2024
|
Balaji Gandhi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
948
-0.97%
|
$20,856
$22.86 P/Share
|
|
Apr 10
2024
|
Janet Gunzburg Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,768
-7.12%
|
$63,664
$23.1 P/Share
|
|
Apr 09
2024
|
Allison C Hoffman General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
4,626
-3.27%
|
$106,398
$23.42 P/Share
|
|
Apr 09
2024
|
Evan Roberts Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
23,330
+2.99%
|
$46,660
$2.03 P/Share
|
|
Apr 09
2024
|
Amy Beth Van Duyn SVP, Human Resources |
SELL
Open market or private sale
|
Direct |
3,768
-3.05%
|
$86,664
$23.43 P/Share
|
|
Apr 08
2024
|
Chaim Indig Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
12,043
-0.49%
|
$264,946
$22.82 P/Share
|
|
Apr 08
2024
|
Balaji Gandhi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,778
-3.67%
|
$171,116
$22.82 P/Share
|
|
Apr 08
2024
|
Allison C Hoffman General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
5,549
-1.89%
|
$122,078
$22.82 P/Share
|
|
Apr 08
2024
|
Janet Gunzburg Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,709
-2.11%
|
$37,598
$22.82 P/Share
|
|
Apr 08
2024
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Indirect |
247
-1.62%
|
$5,434
$22.82 P/Share
|
|
Apr 08
2024
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
3,914
-0.93%
|
$86,108
$22.82 P/Share
|
|
Apr 08
2024
|
Evan Roberts Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
7,178
-0.48%
|
$157,916
$22.82 P/Share
|
|
Apr 08
2024
|
Amy Beth Van Duyn SVP, Human Resources |
SELL
Open market or private sale
|
Direct |
3,354
-1.32%
|
$73,788
$22.82 P/Share
|
|
Apr 05
2024
|
Janet Gunzburg Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,477
+9.35%
|
-
|
|
Apr 05
2024
|
Amy Beth Van Duyn SVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
7,122
+5.32%
|
-
|
|
Apr 05
2024
|
David Linetsky SVP, Life Sciences |
BUY
Grant, award, or other acquisition
|
Indirect |
508
+6.26%
|
-
|
|
Apr 05
2024
|
David Linetsky SVP, Life Sciences |
BUY
Grant, award, or other acquisition
|
Direct |
6,105
+2.82%
|
-
|
|
Apr 05
2024
|
Balaji Gandhi Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,926
+10.12%
|
-
|
|
Apr 05
2024
|
Evan Roberts Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,210
+1.62%
|
-
|
|
Apr 05
2024
|
Allison C Hoffman General Counsel & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
10,175
+6.47%
|
-
|
|
Apr 05
2024
|
Chaim Indig Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,961
+1.67%
|
-
|
|
Mar 25
2024
|
Balaji Gandhi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,504
-3.59%
|
$80,592
$23.21 P/Share
|
|
Mar 21
2024
|
Evan Roberts Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
25,962
-1.72%
|
$597,126
$23.97 P/Share
|
|
Mar 20
2024
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Indirect |
30
-0.42%
|
$690
$23.66 P/Share
|
|
Mar 20
2024
|
Janet Gunzburg Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
137
-0.35%
|
$3,151
$23.66 P/Share
|
|
Mar 19
2024
|
Janet Gunzburg Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,817
-6.49%
|
$64,791
$23.27 P/Share
|